Biocon Biologics, Viatris launch interchangeable biosimilars in US


Biocon Ltd. said that its subsidiary — Biocon Biologics and Viatris have launched interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product in the US.

The two products help regulate high blood sugar in adult as well as pediatric patients having type 1 diabetes and adults suffering from type 2 diabetes.

See also  Chevron buys majority stake in Advanced Clean Energy Storage project in Delta

According to Biocon, the biosimilar products are available in vial and prefilled pen presentations. They can be interchanged for the reference brand — LANTUS (insulin glargine), thereby enabling substitution at the pharmacy counter.

Co-developed by Biocon Biologics and Viatris, SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) are presently available in the US market.

See also  American tech firm indie Semiconductor to buy GEO Semiconductor

The presently marketed non-interchangeable SEMGLEE (insulin glargine) is expected to be phased out by the end of this year, said Biocon.

Share This